DESPITE INSULIN THERAPY, MOST PATIENTS WITH TYPE 1 DIABETES (T1D) DO NOT ACHIEVE THEIR GLYCAEMIC GOAL

DESPITE INSULIN THERAPY, MOST PATIENTS WITH T1D ARE NOT AT GLYCAEMIC GOAL
DESPITE INSULIN THERAPY, MOST PATIENTS WITH T1D ARE NOT AT GLYCAEMIC GOAL

The majority of patients were above target HbA1c levels.1

A high proportion of patients outside the United States were also insufficiently controlled

  • In the EURIODIAB study, of the 2,764 patients from 31 centres in 16 European countries, the mean HbA1c was 8.4%3

 

HYPOGLYCAEMIA IS A MAJOR RISK AND FEAR FOR PATIENTS WITH T1D

Intensification of insulin therapy is associated with an increased risk of severe hypoglycaemia

  • The Incidence of severe hypoglycaemia was approximately 3x higher in the intensive therapy group vs the conventional therapy group in the Diabetes Control and Complications Trial (P<0.001)4

Controlling glycaemic variability is an important part of managing HbA1c levels

  • Time out of range places patients with T1D at risk of hypoglycaemia and postprandial hyperglycaemia.* It can also impact their day-to-day quality of life5†

*Time in range is considered to be time spent within 70–180 mg/dL.5

WEIGHT GAIN IS A GROWING ISSUE AMONG THE T1D POPULATION

Between enrolment (2010–2012) and the updated data (2012–2014), the percentage of overweight or obese patients increased from 24% to 46%1,6

Overweight/obese patients with T1D Updated data from the T1D Exchange Clinic Registry<sup>1,6</sup>
Overweight/obese patients with T1D Updated data from the T1D Exchange Clinic Registry<sup>1,6</sup>

**Forxiga is only indicated in adult T1D patients with body mass index ≥27 kg/m2.7

 

THE FORXIGA
T1D PATIENT

References:

  1. Miller KM, Foster NC, Beck RW, et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015;38(6):971–978.
  2. American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes— 2018. Diabetes Care. 2018;41(suppl 1):S55-S64.
  3. Schoenaker DA, Simon D, Chaturvedi N, et al. Glycemic control and all-cause mortality risk in type 1 diabetes patients: the EURODIAB prospective complications study. J Clin Endocrinol Metab. 2014;99(3):800–807.
  4. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–986.
  5. Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40(12):1631–1640.
  6. Beck RW, Tamborlane WV, Bergenstal RM, et al. The T1D Exchange clinic registry. J Clin Endocrinol Metab. 2012;97(12):4383–4389.
  7. Forxiga. Summary of Product Characteristics. 2019. AstraZeneca.